![]() |
APLS | Apellis Pharmaceuticals, Inc. |
Pharmaceutical Preparations |
Book value per $ invested | $ 0.19 |
Leverage | 75.89% |
Market Cap | $ 3.3B |
PE | 0.00 |
Dividend Yield | 0.00% |
Profit | $ -223.3m |
Margin | -28.93% |
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.